Biomaterial Database

Accumulation of lysosphingolipids in tissues from patients with GM1 and GM2 gangliosidoses. 1992

T Kobayashi, and I Goto, and S Okada, and T Orii, and K Ohno, and T Nakano

Department of Neurology, Faculty of Medicine, Kyushu University, Fukuoka, Japan.

By using a sensitive method, we assayed lysocompounds of gangliosides and asialogangliosides in tissues from four patients with GM2 gangliosidosis (one with Sandhoff disease and three with Tay-Sachs disease) and from three patients with GM1 gangliosidosis [one with infantile type (fetus), one with late-infantile, and one with adult type]. In the brain and spinal cord of all the patients except for an adult GM1 gangliosidosis patient, abnormal accumulation of the lipids was observed, though the concentration in the fetal tissue was low. In GM2 gangliosidosis, the amounts of lyso GM2 ganglioside accumulated in the brain were similar among the patient with Sandhoff disease and the patients with Tay-Sachs disease, whereas the concentration of asialo lyso GM2 ganglioside in the brain was higher in the former patient than in the latter patients. By comparing the sphingoid bases of neutral sphingolipids, gangliosides, and lysosphingolipids, it was suggested that lysosphingolipids in the diseased tissue are synthesized by sequential glycosylation from free sphingoid bases, but not by deacylation of the sphingolipids. Because lysosphingolipids are known to be cytotoxic, the abnormally accumulated lysophingolipids may well be the pathogenetic agent for the neuronal degeneration in gangliosidoses.

UI	MeSH Term	Description	Entries
D012016	Reference Values	The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality.	Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D001921	Brain	The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM.	Encephalon
D002851	Chromatography, High Pressure Liquid	Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed.	Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D005732	Gangliosides	A subclass of ACIDIC GLYCOSPHINGOLIPIDS. They contain one or more sialic acid (N-ACETYLNEURAMINIC ACID) residues. Using the Svennerholm system of abbrevations, gangliosides are designated G for ganglioside, plus subscript M, D, or T for mono-, di-, or trisialo, respectively, the subscript letter being followed by a subscript arabic numeral to indicated sequence of migration in thin-layer chromatograms. (From Oxford Dictionary of Biochemistry and Molecular Biology, 1997)	Ganglioside,Sialoglycosphingolipids
D006028	Glycosphingolipids	Lipids containing at least one monosaccharide residue and either a sphingoid or a ceramide (CERAMIDES). They are subdivided into NEUTRAL GLYCOSPHINGOLIPIDS comprising monoglycosyl- and oligoglycosylsphingoids and monoglycosyl- and oligoglycosylceramides; and ACIDIC GLYCOSPHINGOLIPIDS which comprises sialosylglycosylsphingolipids (GANGLIOSIDES); SULFOGLYCOSPHINGOLIPIDS (formerly known as sulfatides), glycuronoglycosphingolipids, and phospho- and phosphonoglycosphingolipids. (From IUPAC's webpage)	Asialoganglioside,Asialogangliosides,Glycosphingolipid,Sphingoglycolipid,Sphingoglycolipids
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012497	Sandhoff Disease	An autosomal recessive neurodegenerative disorder characterized by an accumulation of G(M2) GANGLIOSIDE in neurons and other tissues. It is caused by mutation in the common beta subunit of HEXOSAMINIDASE A and HEXOSAMINIDASE B. Thus this disease is also known as the O variant since both hexosaminidase A and B are missing. Clinically, it is indistinguishable from TAY-SACHS DISEASE.	G(M2) Gangliosidosis, Type II,Gangliosidosis G(M2), Type II,Hexosaminidase A and B Deficiency Disease,Adult Sandhoff Disease,Deficiency Disease, Hexosaminidase A and B,GM2 Gangliosidosis, Type 2,GM2 Gangliosidosis, Type II,GM2-Gangliosidosis, Type II,Gangliosidosis GM2, Type II,Hexosaminidases A And B Deficiency,Infantile Sandhoff Disease,Juvenile Sandhoff Disease,Sandhoff Disease, Adult,Sandhoff Disease, Adult Type,Sandhoff Disease, Infantile,Sandhoff Disease, Infantile Type,Sandhoff Disease, Juvenile,Sandhoff Disease, Juvenile Type,Sandhoff's Disease,Sandhoff-Jatzkewitz-Pilz Disease,Total Hexosaminidase Deficiency,beta-Hexosaminidase-beta-Subunit Deficiency,Deficiency, Total Hexosaminidase,Deficiency, beta-Hexosaminidase-beta-Subunit,Disease, Sandhoff-Jatzkewitz-Pilz,GM2-Gangliosidoses, Type II,Hexosaminidase Deficiency, Total,Sandhoff Jatzkewitz Pilz Disease,Sandhoffs Disease,Total Hexosaminidase Deficiencies,Type II GM2-Gangliosidoses,Type II GM2-Gangliosidosis,beta Hexosaminidase beta Subunit Deficiency,beta-Hexosaminidase-beta-Subunit Deficiencies
D013107	Sphingolipids	A class of membrane lipids that have a polar head and two nonpolar tails. They are composed of one molecule of the long-chain amino alcohol sphingosine (4-sphingenine) or one of its derivatives, one molecule of a long-chain acid, a polar head alcohol and sometimes phosphoric acid in diester linkage at the polar head group. (Lehninger et al, Principles of Biochemistry, 2nd ed)	Lysosphingolipids,Sphingolipid
D013110	Sphingosine	An amino alcohol with a long unsaturated hydrocarbon chain. Sphingosine and its derivative sphinganine are the major bases of the sphingolipids in mammals. (Dorland, 28th ed)	4-Sphingenine,4 Sphingenine
D013661	Tay-Sachs Disease	An autosomal recessive neurodegenerative disorder characterized by the onset in infancy of an exaggerated startle response, followed by paralysis, dementia, and blindness. It is caused by mutation in the alpha subunit of the HEXOSAMINIDASE A resulting in lipid-laden ganglion cells. It is also known as the B variant (with increased HEXOSAMINIDASE B but absence of hexosaminidase A) and is strongly associated with Ashkenazic Jewish ancestry.	G(M2) Gangliosidosis, Type I,Gangliosidosis G(M2), Type I,Gangliosidosis GM2, B Variant,Hexosaminidase A Deficiency Disease,Tay-Sachs Disease, B Variant,Amaurotic Familial Idiocy,B Variant GM2 Gangliosidosis,B Variant GM2-Gangliosidosis,Deficiency Disease Hexosaminidase A,Familial Amaurotic Idiocy,GM2 Gangliosidosis, B Variant,GM2 Gangliosidosis, Type 1,GM2 Gangliosidosis, Type I,GM2-Gangliosidosis, Type I,Gangliosidosis GM2 , Type 1,Gangliosidosis GM2, Type I,HexA Deficiency,Hexosaminidase A Deficiency,Hexosaminidase alpha-Subunit Deficiency (Variant B),Sphingolipidosis, Tay-Sachs,Amaurotic Idiocy, Familial,B Variant GM2-Gangliosidoses,Deficiency, Hexosaminidase A,Deficiency, Hexosaminidase alpha-Subunit (Variant B),GM2-Gangliosidosis, B Variant,Hexosaminidase alpha Subunit Deficiency (Variant B),Sphingolipidosis, Tay Sachs,Tay Sachs Disease,Tay Sachs Disease, B Variant,Tay-Sachs Sphingolipidosis,Type I GM2-Gangliosidosis

Related Publications

T Kobayashi, and I Goto, and S Okada, and T Orii, and K Ohno, and T Nakano

Neurophysiological investigations in GM1 and GM2 gangliosidoses.

September 1984, Neuropediatrics,

T Kobayashi, and I Goto, and S Okada, and T Orii, and K Ohno, and T Nakano

The GM1 and GM2 Gangliosidoses: Natural History and Progress toward Therapy.

June 2016, Pediatric endocrinology reviews : PER,

T Kobayashi, and I Goto, and S Okada, and T Orii, and K Ohno, and T Nakano

Increased concentration of GM1-ganglioside in cerebrospinal fluid in dogs with GM1- and GM2-gangliosidoses and its clinical application for diagnosis.

May 2004, Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc,

T Kobayashi, and I Goto, and S Okada, and T Orii, and K Ohno, and T Nakano

Nomenclature of GM2-gangliosidoses.

May 1980, Clinical genetics,

T Kobayashi, and I Goto, and S Okada, and T Orii, and K Ohno, and T Nakano

[New studies in GM2 gangliosidoses].

October 1975, Harefuah,

T Kobayashi, and I Goto, and S Okada, and T Orii, and K Ohno, and T Nakano

Natural history study of glycan accumulation in large animal models of GM2 gangliosidoses.

January 2020, PloS one,

T Kobayashi, and I Goto, and S Okada, and T Orii, and K Ohno, and T Nakano

The diagnostic journey for patients with late-onset GM2 Gangliosidoses.

December 2023, Molecular genetics and metabolism reports,